BCMA-targeted CAR T-cells NTCC? BCMA靶點CAR T細胞

BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

BCMA-targeted CAR T-cells are a revolutionary form of immunotherapy that has shown significant promise in the treatment of multiple myeloma (MM), a type of bone marrow cancer.

Opens in a new windowmy.clevelandclinic.org

Multiple Myeloma cancer cells

How do BCMA-targeted CAR T-cells work?

• BCMA (B-cell maturation antigen): This protein is primarily found on the surface of plasma cells, the malignant cells in MM.

  

  BCMA protein

  
  

• CAR T-cells: These are a patient's own T-cells (a type of white blood cell) that have been genetically engineered to express a chimeric antigen receptor (CAR).

  

  CAR Tcell structure

  
  

  CAR: This synthetic receptor allows the T-cell to specifically recognize and bind to BCMA on the surface of MM cells.

  
  

  
  

• T-cell activation: Once the CAR binds to BCMA, it triggers the T-cell to attack and kill the MM cell.

Key advantages of BCMA-targeted CAR T-cell therapy:

• High specificity: CAR T-cells target only MM cells that express BCMA, minimizing damage to healthy cells.

• Potent anti-tumor activity: They can effectively eliminate MM cells, even in patients with relapsed or refractory disease.

• Durable responses: In some patients, CAR T-cells can persist for a long time, providing sustained protection against MM.

Challenges and limitations:

• Cytokine release syndrome (CRS): This is a serious side effect that can occur after CAR T-cell infusion, characterized by high fevers, low blood pressure, and organ dysfunction.

• Neurological toxicities: Some patients may experience neurological symptoms such as confusion, seizures, or encephalopathy.

• High cost: The manufacturing process for CAR T-cells is complex and expensive.

• Potential for resistance: MM cells may develop mechanisms to evade CAR T-cell attack.

Future directions:

• Next-generation CAR T-cells: Researchers are developing new CAR T-cell designs to improve efficacy and reduce side effects.

• Combination therapies: Combining CAR T-cells with other treatments, such as chemotherapy or checkpoint inhibitors, may enhance their effectiveness.

• Targeted therapies: Identifying biomarkers that predict which patients are most likely to benefit from CAR T-cell therapy can help optimize treatment decisions.

生產廠家Supplier:

BioVector NTCC質粒載體菌株細胞蛋白抗體基因保藏中心

E-mail:BioVector@163.com

http://www.biovector.net